Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | PRKACA | P17612 | 3/20 | 1.00 |
| ▸ | PRKACG | P22612 | 3/20 | 1.00 |
| ▸ | PRKACB | P22694 | 3/20 | 1.00 |
| ▸ | CCL2 | P13500 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 2/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ACAD10 | Q6JQN1 | 1/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.73 |
| ▸ | MYLK | Q15746 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyfasudil SCHEMBL29395466 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| Hydroxyfasudil SCHEMBL16499912 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL29351112 | 0.84 | ROCK1 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL1271163 | 0.84 | ROCK1 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL29651499 | 0.83 | LMNA (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL30237215 | 0.83 | LMNA (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL3691324 | 0.83 | LMNA (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL2869228 | 0.83 | CYP3A4 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL1981350 | 0.82 | ROCK1 (0.95) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL1848494 | 0.82 | MAPK1 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1057 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746855-A1 | FORMULATIONS AND USES OF ROCK2 INHIBITORS FOR ALS | Graviton Bioscience BV (NL) | 2026-05-27 | — | — | EP | claimed |
| CN-122094667-A | Formulations and uses of ROCK2 inhibitors for ALS | — | 2026-05-26 | — | — | CN | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090172-A1 | CELL CULTURE SYSTEMS COMPRISING MICROPATTERNED ARRAYS AND METHODS OF USE | ALTIS BIOSYSTEMS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-3294871-B1 | COMBINATION OF PHARMACOLOGICAL AND MICROFLUIDIC FEATURES FOR IMPROVED PLATELETS PRODUCTION | HEMOSTOD SA (CH) | 2026-04-29 | — | — | EP | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | claimed |
| US-20100009364-A1 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2010-01-14 | — | — | US | claimed |
| WO-2010006291-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT | NODALITY, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20090098594-A1 | Methods for diagnosis prognosis and methods of treatment | NODALITY, INC. (US) | 2009-04-16 | — | — | US | claimed |
| WO-2009042956-A1 | CONTROL OF SPORE GERMINATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-04-02 | — | — | WO | claimed |
| WO-2009025847-A2 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | claimed |
| US-20050014783-A1 | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-20 | — | — | US | claimed |
| US-20040266755-A1 | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-30 | — | — | US | claimed |
| WO-2004105757-A2 | USE OF RHO-KINASE INHIBITORS IN THE TREATMENT OF ANEURYSM AND CARDIAC HYPERTROPHY | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004106325-A1 | PRODRUGS OF 1-(1-HYDROXY-5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266755-A1 | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine | HTR5A, CYP2S1, CYP3A5 | ROCK2 3996/4885ROCK1 2844/4885PRKACA 4544/4885 |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | MTCL3, DYNLL2, CEP170 | ROCK2 166/4885ROCK1 282/4885PRKACA 171/4885 |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | ROCK2 341/4885ROCK1 238/4885PRKACA 1713/4885 |
| US-20050014783-A1 | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885PRKACA 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.